CYB5B

Summary

CYB5B (cytochrome b5 type B, HGNC:24374) is a protein-coding gene on chromosome 16q22.1, encoding Cytochrome b5 type B (O43169). Cytochrome b5 is a membrane-bound hemoprotein functioning as an electron carrier for several membrane-bound oxygenases. It is a selective cancer dependency (DepMap: 24.7% of cell lines).

Enables heme binding activity. Contributes to nitrite reductase (NO-forming) activity. Involved in nitric oxide biosynthetic process. Located in membrane. Part of nitric-oxide synthase complex.

Source: NCBI Gene 80777 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 43 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 24.7% of screened cell lines
• MANE Select transcript: NM_030579

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24374
Approved symbol	CYB5B
Name	cytochrome b5 type B
Location	16q22.1
Locus type	gene with protein product
Status	Approved
Aliases	CYB5-M
Ensembl gene	ENSG00000103018
Ensembl biotype	protein_coding
OMIM	611964
Entrez	80777

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 12 protein_coding, 3 retained_intron, 3 nonsense_mediated_decay

ENST00000307892, ENST00000514123, ENST00000515314, ENST00000561792, ENST00000568237, ENST00000568342, ENST00000684784, ENST00000686167, ENST00000686649, ENST00000687677, ENST00000687780, ENST00000688840, ENST00000689149, ENST00000691260, ENST00000692523, ENST00000692677, ENST00000693607, ENST00000944290

RefSeq mRNA: 1 — MANE Select: NM_030579 NM_030579

CCDS: CCDS10880

Canonical transcript exons

ENST00000307892 — 5 exons

Exon	Start	End
ENSE00001031836	69459093	69459121
ENSE00002268884	69462430	69466264
ENSE00002322000	69424619	69424857
ENSE00003495597	69447150	69447278
ENSE00003640984	69448115	69448144

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 81.9281 / max 1418.2269, expressed in 1822 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154818	51.3248	1816
154817	27.2060	1809
154816	3.3974	1599

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.39	gold quality
right adrenal gland	UBERON:0001233	99.30	gold quality
left adrenal gland	UBERON:0001234	99.21	gold quality
left adrenal gland cortex	UBERON:0035825	99.18	gold quality
adrenal tissue	UBERON:0018303	99.15	gold quality
adrenal cortex	UBERON:0001235	99.12	gold quality
adrenal gland	UBERON:0002369	98.91	gold quality
rectum	UBERON:0001052	98.09	gold quality
mucosa of transverse colon	UBERON:0004991	96.23	gold quality
ganglionic eminence	UBERON:0004023	96.12	gold quality
metanephros cortex	UBERON:0010533	96.01	gold quality
stromal cell of endometrium	CL:0002255	96.00	gold quality
islet of Langerhans	UBERON:0000006	95.87	gold quality
ventricular zone	UBERON:0003053	95.59	gold quality
gall bladder	UBERON:0002110	95.31	gold quality
prefrontal cortex	UBERON:0000451	94.92	gold quality
cortical plate	UBERON:0005343	94.84	gold quality
transverse colon	UBERON:0001157	94.63	gold quality
ectocervix	UBERON:0012249	94.26	gold quality
embryo	UBERON:0000922	94.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.22	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.14	gold quality
upper lobe of left lung	UBERON:0008952	94.11	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.06	gold quality
endocervix	UBERON:0000458	94.02	gold quality
amygdala	UBERON:0001876	93.91	gold quality
cingulate cortex	UBERON:0003027	93.91	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.89	gold quality
anterior cingulate cortex	UBERON:0009835	93.84	gold quality
upper lobe of lung	UBERON:0008948	93.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ENAD-20	no	314.94
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

134 targeting CYB5B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-182-5P	99.87	74.03	2589

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 24.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• could be involved in the differential modulation of 17 alpha-hydroxylase and 17,20-lyase activities of P450c17 [type2 cyt-b5] (PMID:11867265)
• The 21 kDa protein overexpressed in Hodgkin Lymphoma and aggressive non-Hodgkin Lymphomas is identical to CYB5B. (PMID:20100355)
• comparison of X-ray crystal structures of human and rat CYB5B reveals a striking difference in packing involving the five-strand beta-sheet, which can be attributed to fully buried residue 21 in strand beta4 (PMID:21574570)
• Data indicate that mitochondrial amidoxime reducing components 1 and 2 together with the electron transport proteins NADH-cytochrome b5 reductase (CYB5R) and cytochrome b5 (CYB5) catalyze the reduction of N-hydroxylated compounds such as amidoximes. (PMID:23703616)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyb5b	ENSDARG00000099774
mus_musculus	Cyb5b	ENSMUSG00000031924
rattus_norvegicus	Cyb5b	ENSRNOG00000011142
drosophila_melanogaster	CG3566	FBGN0029854
caenorhabditis_elegans		WBGENE00007848

Paralogs (1): CYB5A (ENSG00000166347)

Protein

Protein identifiers

Cytochrome b5 type B — O43169 (reviewed: O43169)

Alternative names: Cytochrome b5 outer mitochondrial membrane isoform

All UniProt accessions (12): O43169, A0A8I5KP74, A0A8I5KSY3, A0A8I5KSY8, A0A8I5KVH4, A0A8I5KX20, A0A8I5KYK4, A0A8I5QJ67, A0A8I5QKN7, D6RFH4, H3BUX2, J3QR91

UniProt curated annotations — full annotation on UniProt →

Function. Cytochrome b5 is a membrane-bound hemoprotein functioning as an electron carrier for several membrane-bound oxygenases.

Subunit / interactions. Component of a complex composed of cytochrome b5, NADH-cytochrome b5 reductase (CYB5R3) and MTARC2.

Subcellular location. Mitochondrion outer membrane.

Similarity. Belongs to the cytochrome b5 family.

RefSeq proteins (1): NP_085056* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001199	Cyt_B5-like_heme/steroid-bd	Domain
IPR018506	Cyt_B5_heme-BS	Binding_site
IPR036400	Cyt_B5-like_heme/steroid_sf	Homologous_superfamily
IPR050668	Cytochrome_b5	Family

Pfam: PF00173

UniProt features (25 total): helix 7, modified residue 5, strand 3, turn 2, binding site 2, propeptide 1, chain 1, sequence conflict 1, transmembrane region 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3NER	X-RAY DIFFRACTION	1.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43169-F1	82.12	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 59 (axial binding residue); 83 (axial binding residue)

Post-translational modifications (5): 39, 84, 23, 34, 37

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1660661	Sphingolipid de novo biosynthesis
R-HSA-203615	eNOS activation
R-HSA-211945	Phase I - Functionalization of compounds

MSigDB gene sets: 226 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, REACTOME_BIOLOGICAL_OXIDATIONS, chr16q22, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, UEDA_PERIFERAL_CLOCK, WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP, MODULE_239, GOBP_REACTIVE_NITROGEN_SPECIES_METABOLIC_PROCESS, ACATTCC_MIR1_MIR206, GOCC_MITOCHONDRIAL_ENVELOPE, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN

GO Biological Process (3): xenobiotic metabolic process (GO:0006805), nitric oxide biosynthetic process (GO:0006809), response to oxidative stress (GO:0006979)

GO Molecular Function (4): heme binding (GO:0020037), metal ion binding (GO:0046872), protein binding (GO:0005515), nitrite reductase (NO-forming) activity (GO:0050421)

GO Cellular Component (5): mitochondrial outer membrane (GO:0005741), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), nitric-oxide synthase complex (GO:1903958), mitochondrion (GO:0005739)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Sphingolipid metabolism	1
Metabolism of nitric oxide: NOS3 activation and regulation	1
Biological oxidations	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
cellular response to xenobiotic stimulus	1
biosynthetic process	1
nitric oxide metabolic process	1
response to stress	1
tetrapyrrole binding	1
cation binding	1
binding	1
oxidoreductase activity, acting on other nitrogenous compounds as donors, cytochrome as acceptor	1
nitrite reductase activity	1
mitochondrial membrane	1
organelle outer membrane	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1
oxidoreductase complex	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

3261 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYB5B	POR	P16435	997
CYB5B	CYCS	P00001	995
CYB5B	CYB5RL	Q6IPT4	994
CYB5B	CYB5R3	P00387	993
CYB5B	CYB5R2	Q6BCY4	993
CYB5B	CYB5R1	Q9UHQ9	993
CYB5B	MB	P02144	989
CYB5B	SCD	O00767	984
CYB5B	CYP17A1	P05093	979
CYB5B	CYB5R4	Q7L1T6	965
CYB5B	NENF	Q9UMX5	962
CYB5B	CYP3A4	P05184	920
CYB5B	FADS3	Q9Y5Q0	901
CYB5B	CYP2B6	P20813	896
CYB5B	CYP2E1	P05181	894

IntAct

197 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CYB5B	MFSD5	psi-mi:“MI:0915”(physical association)	0.670
CYB5B	EBP	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	CGRRF1	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	STX1A	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	BNIP3L	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	MFF	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	BIK	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	AHNAK2	psi-mi:“MI:0915”(physical association)	0.560
	CYB5B	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	TMEM237	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	CYB5B	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	STOM	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	SDHAF4	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	MARCHF8	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	PDZK1IP1	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	TMEM139	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	PHACTR3	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	BTNL9	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	MFSD4B	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	CLDN7	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	GPR152	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	TMEM35A	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	KCNK5	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	SLC39A9	psi-mi:“MI:0915”(physical association)	0.560
CYB5B	RETREG3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (366): CYB5B (Affinity Capture-RNA), CYB5B (Affinity Capture-RNA), CYB5B (Affinity Capture-RNA), CCDC47 (Co-fractionation), CCT2 (Co-fractionation), CYB5B (Co-fractionation), CYB5B (Co-fractionation), CYB5B (Co-fractionation), CYB5B (Co-fractionation), CYB5B (Co-fractionation), CYB5R1 (Co-fractionation), CYB5R3 (Co-fractionation), CYCS (Co-fractionation), ISYNA1 (Co-fractionation), PHB2 (Co-fractionation)

ESM2 similar proteins: B7G7Y7, B7GCG7, O04354, O13995, O22704, O43169, O48845, O74875, O94391, P00167, P00169, P00170, P00171, P00172, P00173, P00174, P00175, P04166, P34454, P34476, P35848, P40312, P40934, P49096, P49097, P49098, P49099, P49100, P56395, Q10352, Q12091, Q29HF1, Q42342, Q54LA1, Q55CU8, Q5RDJ5, Q60YT6, Q7YZW5, Q874I5, Q9CQX2

Diamond homologs: A0A0C5PRW9, A4FV48, A4IFP3, A4UVI1, A8MWK0, B2KKL4, B7GCG7, B8MKR3, B8R1K0, C8VJR5, D8X2C5, O04354, O22704, O43169, O48845, O60427, O74875, O94391, O95864, P00167, P00168, P00169, P00170, P00171, P00172, P00173, P00174, P00175, P04166, P09437, P32953, P40312, P40934, P49096, P49097, P49098, P49099, P49100, P56395, P82291

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neutrophil degranulation	10	3.5×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1112 predictions. Top by Δscore:

Variant	Effect	Δscore
16:69447146:GTAGC:G	acceptor_loss	1.0000
16:69447147:TAGC:T	acceptor_loss	1.0000
16:69447148:A:AG	acceptor_gain	1.0000
16:69447149:G:GG	acceptor_gain	1.0000
16:69447149:GC:G	acceptor_gain	1.0000
16:69447149:GCA:G	acceptor_gain	1.0000
16:69447149:GCACC:G	acceptor_gain	1.0000
16:69447268:A:AG	donor_gain	1.0000
16:69447276:CCGG:C	donor_loss	1.0000
16:69447277:CGGTA:C	donor_loss	1.0000
16:69447278:GGT:G	donor_loss	1.0000
16:69447279:G:GC	donor_loss	1.0000
16:69447280:T:A	donor_loss	1.0000
16:69424738:G:GT	donor_gain	0.9900
16:69424778:TGGCA:T	donor_gain	0.9900
16:69424801:G:GT	donor_gain	0.9900
16:69424825:C:T	donor_gain	0.9900
16:69424856:AG:A	donor_loss	0.9900
16:69424857:GGT:G	donor_loss	0.9900
16:69424858:GTGG:G	donor_loss	0.9900
16:69424859:T:G	donor_loss	0.9900
16:69438362:TGTAC:T	donor_gain	0.9900
16:69438363:GTACA:G	donor_gain	0.9900
16:69447149:GCAC:G	acceptor_gain	0.9900
16:69447279:G:GG	donor_gain	0.9900
16:69448113:A:AG	acceptor_gain	0.9900
16:69448114:G:GG	acceptor_gain	0.9900
16:69448114:GA:G	acceptor_gain	0.9900
16:69448114:GAGT:G	acceptor_gain	0.9900
16:69448142:AAGGT:A	donor_loss	0.9900

AlphaMissense

974 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:69447207:T:C	F78L	0.999
16:69447209:T:A	F78L	0.999
16:69447209:T:G	F78L	0.999
16:69447224:C:A	H83Q	0.999
16:69447224:C:G	H83Q	0.999
16:69424846:T:C	F55L	0.998
16:69424847:T:C	F55S	0.998
16:69424848:C:A	F55L	0.998
16:69424848:C:G	F55L	0.998
16:69447151:A:G	H59R	0.998
16:69447152:C:A	H59Q	0.998
16:69447152:C:G	H59Q	0.998
16:69447222:C:G	H83D	0.998
16:69424829:T:A	V49D	0.997
16:69447157:G:A	G61E	0.997
16:69447208:T:C	F78S	0.997
16:69447222:C:A	H83N	0.997
16:69447223:A:G	H83R	0.997
16:69447265:G:A	G97D	0.997
16:69447265:G:T	G97V	0.997
16:69424847:T:G	F55C	0.996
16:69447150:C:G	H59D	0.996
16:69447172:T:C	L66P	0.996
16:69447208:T:G	F78C	0.996
16:69424831:T:G	Y50D	0.995
16:69447153:C:T	P60S	0.995
16:69447196:C:A	A74E	0.995
16:69447235:C:A	A87D	0.995
16:69447247:T:C	L91P	0.995
16:69447154:C:A	P60H	0.994

dbSNP variants (sampled 300 via entrez): RS1000103820 (16:69465038 C>G,T), RS1000175284 (16:69454924 C>T), RS1000204390 (16:69440904 C>G,T), RS1000251785 (16:69427873 G>A), RS1000276251 (16:69422636 G>C), RS1000313561 (16:69460933 T>A), RS1000342572 (16:69445905 G>A), RS1000406588 (16:69447769 A>G), RS1000454511 (16:69460568 G>T), RS1000516150 (16:69440834 T>A), RS1000588346 (16:69440460 G>C,T), RS1000604410 (16:69446087 T>C), RS1000692698 (16:69427633 C>T), RS1000804520 (16:69433670 G>A), RS1000809466 (16:69439274 G>A,C,T)

Disease associations

OMIM: gene MIM:611964 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST002251_8	Homeostasis model assessment of beta-cell function (dietary factor interaction)	9.000000e-06
GCST002587_28	Blood pressure (smoking interaction)	4.000000e-09
GCST004267_1	Blood osmolality (transformed sodium)	6.000000e-12
GCST004267_7	Blood osmolality (transformed sodium)	6.000000e-10
GCST005951_13	Body mass index	5.000000e-11
GCST005983_5	Serum uric acid levels	1.000000e-08
GCST006979_629	Heel bone mineral density	5.000000e-11
GCST007725_38	Serum uric acid levels	3.000000e-07
GCST007733_19	Serum uric acid levels	7.000000e-08
GCST007733_56	Serum uric acid levels	2.000000e-10

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004469	HOMA-B
EFO:0008111	diet measurement
EFO:0006335	systolic blood pressure
EFO:0006526	pack-years measurement
EFO:0004340	body mass index
EFO:0004761	uric acid measurement
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523134 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

77 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
perfluorooctanoic acid	decreases expression	2
perfluorooctane sulfonic acid	decreases expression	2
Acetaminophen	decreases expression	2
Air Pollutants	affects expression, affects cotreatment, increases abundance, increases expression	2
Cadmium	decreases reaction, increases abundance, increases palmitoylation, increases expression	2
Ozone	increases abundance, affects expression, affects cotreatment, increases expression	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation, increases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
bisphenol A	affects expression	1
N(4)-hydroxycytidine	affects cotreatment, increases reduction	1
dibutylnitrosamine	affects cotreatment, increases response to substance	1
N-nitroso(di-n-propyl)amine	affects cotreatment, increases response to substance	1
beta-lapachone	decreases expression	1
sodium arsenite	affects cotreatment, increases expression	1
cobaltous chloride	decreases expression	1
N(4)-hydroxycytosine	affects cotreatment, increases reduction	1
2-bromopalmitate	increases abundance, increases palmitoylation, decreases reaction	1
sulindac sulfide	decreases expression	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
benzamidoxime	affects cotreatment, increases reduction	1
phenethyl isothiocyanate	affects binding	1
sulfamethoxazole hydroxylamine	affects cotreatment, increases reduction	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4341383	Binding	Binding affinity to CYB5B in human A549 cells lysates grown on SILAC media at 10 uM incubated for 1 hr by LC-MS/MS analysis	Profiling withanolide A for therapeutic targets in neurodegenerative diseases. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.